Drug Discovery

Everest Medicines Completes Patient Enrollment for Nefecon® China Study

The cOLE study offers an additional 9 months of treatment with Nefecon® to all qualifying patients who have completed the NefIgArd study and will evalu...

 August 01, 2023 | News

Lupin Pharmaceuticals Recalls 2 Lots of TydemyTM Due to OOS Results

Lupin Pharmaceuticals Inc. (Lupin) is voluntarily recalling two (2) lots of Tydemy (Drospirenone, Ethinyl Estradiol and Levomefolate Calcium Tablets 3mg/0....

 July 31, 2023 | News

Transcenta's Anti-sclerostin Antibody TST002 Approved for Phase II Trial in China for Reduced Bone Density Patients

This study aims to evaluate the safety, tolerability, and pharmacokinetics of TST002(Blosozumab) after single and multiple intravenous administrations in p...

 July 31, 2023 | News

RenovoRx and Imugene Join Forces for Oncolytic Virus Therapy Using TAMP Platform

Collaboration will explore trans-arterial delivery of Imugene's CF33 oncolytic virus utilizing RenovoRx's TAMP therapy platform TAMP enables localized, ...

 July 25, 2023 | News

China's Mabwell Announces NMPA Approval of Novel B7-H3 ADC (7MW3711) for IND

B7-H3 is a member of the B7 ligand family and is overexpressed in most cancer types but expressed at a low level in normal tissues. In malignant tissues, B...

 July 24, 2023 | News

Insilico Medicine Nominates Preclinical Candidate for ISM001-055, First Generative AI IPF Drug

  Insilico Medicine merges nebulizer device with AI-driven drug discovery; Potential advantages for the inhalation solution include a smaller effe...

 July 24, 2023 | News

AstraZeneca's Saphnelo Now Available in Malaysia for Adult Autoantibody-Positive SLE

SLE is a chronic and complex autoimmune condition that can affect any organ, and patients often experience inadequate disease control, long-term organ dama...

 July 21, 2023 | News

US FDA Grants Orphan Drug Designation to SN Bioscience's 'SNB-101' for Small Cell Lung Cancer

SNB-101 showed excellent efficacy in animal small cell lung cancer models, and based on this, it has been designated as an orphan drug by the US FDA after ...

 July 21, 2023 | News

Scribe Therapeutics and Sanofi Team Up to Advance In Vivo Genetic Medicines for Sickle Cell and Genomic Disease

Predicated on the progress of the companies’ first collaboration, Sanofi has selected Scribe’s novel CRISPR by Design™ approach to driv...

 July 18, 2023 | News

GeneQuantum and InxMed Partner for Innovative ADC Drug Research

According to the agreement, GeneQuantum will provide InxMed with its independently developed, globally leading technologies in site-specific glycan conjuga...

 July 17, 2023 | News

Antengene's XPOVIO® Approved in Hong Kong for Relapsed Multiple Myeloma

XPOVIO® has received regulatory approvals in 41 countries and regions including the United States, Israel, the United Kingdo...

 July 17, 2023 | News

Biosyngen's First-in-class Cell Therapy BRG01 Receives FDA Fast Track Designation

  Fast Track Designation (FTD) aims to facilitate the development of drugs targeting severe or life-threatening diseases that have the potential to a...

 July 12, 2023 | News

Transcenta Receives Approvals for Global Phase III Trial of Osemitamab (TST001)

To initiate TranStar 301 global Phase III pivotal trial of Osemitamab (TST001) in combination with Nivolumab and chemotherapy for the first-line treatment ...

 July 10, 2023 | News

Hexvix® Completes Phase III Bridging Trial Enrollment for Bladder Cancer

The study is a prospective, self-controlled, multicenter Phase Ⅲ trial aimed at investigating the additional detection rate and safety of Hexvix®&nbs...

 July 10, 2023 | News


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close